Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Disclosure
3. Oncolytic virotherapy
4. Any virus can be adapted
5. Key considerations in oncolytic virotherapy
6. What can we learn from studies of natural virus pathogenesis?
7. Poliovirus pathogenesis in humans and transgenic mice
8. Oncolytic virus examples
9. Measles pathogenesis
10. Origin of MV-NIS, a safe, trackable oncolytic measles virus
11. Durable complete remission of disseminated cancer after a single MV-NIS infusion
12. Anti-measles antibodies negate the efficacy of intravenous MV-NIS
13. Targeting: Receptor-specific measles viruses displaying cell-targeting ligands
14. Targeting an MHC-peptide complex with a measles virus displaying scTCR
15. Discriminating receptor density on target cells using measles viruses
16. Stealthed, targeted, armed measles virus (MV-STAR)
17. Oncolytic virus examples: Vesicular stomatitis virus
18. Vesicular stomatitis virus
19. First-in-human clinical trial of VSV (VSV-IFNβ) as intratumoral therapy
20. Case details: Tumor lysis after intratumoral VSV-IFNβ
21. Postulated MOA for intratumoral VSV
22. Intravenous VSV-IFNβ-NIS
23. Intravenous VSV-IFNβ-NIS: Higher doses are more effective
24. VSV-IFNβ-NIS canine lymphoma trial
25. Human trial of intravenous VSV-IFNβ-NIS in hematologic malignancies
26. Voyager-V1 is active after a single infusion
27. Postulated MOA for intravenous VSV-IFNβ-NIS in T cell lymphoma
28. Combination therapy with VSV-mIFNβ-NIS + αPD1 + αCTLA4 antibodies
29. VSV-IFNβ-NIS in human subjects: Experience to date
30. Oncolytic virus examples: Picornaviruses
31. Infectious picornavirus RNA
32. Coxsackievirus A21
33. Oncolytic virus examples: Herpesviruses
34. Status of the OV field Q1 2023
35. Boosting the clinical efficacy of T-VEC via combination therapy
36. Combining herpesviruses (HSV+CMV) as an alternative approach for boosting OV efficacy
37. HSV1-IL12 + mCMV are synergistic in a bilateral B16-F10-nectin1 model
38. Taking intratumoral OVs to the next level
39. CMV to convert infected cells into lentiviral vector factories
40. Envisioned strategy to use CMV as an oncolytic vector that also delivers lentiviral CAR-T therapy
41. Conclusions
42. Acknowledgments

Topics Covered

• Measles
• Vesicular stomatitis virus
• Picornavirus
• Herpesvirus
• Coxsackievirus
• Cytomegalovirus
• Modified Measles Virus (MV-NIS)
• T cell lymphoma
• Clinical trials
• Voyager-V1
• Talimogene laherparepvec (T-VEC)

Links

Series:

• Gene Transfer and Gene Therapy

Categories:

• Cancer

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on September 28, 2023

Financial Disclosures

• Dr. Russell is a cofounder, shareholder and CEO of Vyriad, a company that is developing and commercializing targeted genetic medicines, including oncolytic virus therapies.